πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11666658

Rifamycin analogs and antibody-drug conjugates thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11655286

Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and met

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11655291

Compositions and methods for increasing muscle mass and muscle strength by specifically an

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11649273

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11642390

Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11640848

Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burde

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11634480

Human antibodies to GREM1

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11633501

Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11629195

Anti-IL2 receptor gamma antigen-binding proteins

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11622547

Genetically modified mouse that expresses human albumin

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11608381

Methods of treatment using a leptin receptor agonist antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11608380

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603413

Anti-TMPRSS2 antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603408

Methods for treating skin infection by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603407

Stable antibody formulation

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596690

Stabilized formulations containing anti-IL-33 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596635

Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11594302

High resolution allele identification

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11590223

Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11584966

Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11579150

Methods for characterizing disulfide bonds

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11578135

Multispecific antigen-binding molecules binding to a target and an internalizing effector

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11578127

Anti-Fc epsilon-R1 alpha (FcΞ΅R1Ξ±) antibodies, bispecific antigen-binding molecules that bi

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11576984

Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted